• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2023.18024

State of the gut microbiota in patients with chronic heart failure

[Reviews]
Elena Vladimirovna Khazova; Dilyara Damirovna Safina;

The study of the human microbiota of the gastrointestinal tract seems to be one of the innovative directions and is considered as a new potential target in the prevention and treatment of cardiovascular diseases. A literature review was conducted on the relationship of the gut microbiota and its metabolites, which may have an adverse effect on human health, with diseases of the cardiovascular continuum. Changes in the composition of the gut microbiota, both quantitative and qualitative, lead to significant disorders of cavitary and membrane digestion, absorption of nutrients, metabolic and immune disorders. The article presents the age-related aspects of changes in the gut microbiota. Gut microbiota alterations was described in patients with dyslipidemia, arterial hypertension, and chronic heart failure. In patients with heart failure, associations between the representation of individual bacteria in the intestinal microbiota and the level of C-reactive protein, NT-proBNP, endothelin, echocardiography indicators were characterized. The study of microbial diversity in heart failure is a promising area of scientific research that opens up new opportunities for the prevention and treatment of cardiovascular diseases.

Download

References:
1. Kashtanova D. A., Tkacheva O. N., Boytsov S. A. Gut microbiota and cardiovascular risk factors. Part 1. Gut microbiota, age and sex. Kardiovaskulyarnaya terapiya i profilaktika. – Cardiovascular therapy and prevention. 2015;14(4):92-95. (In Russ.). https://doi.org/10.15829/1728-8800-2015-4-92-95
2. Bergström A., Skov T. H., Bahl M. I., Roager H. M., Christensen L. B. [et al.]. Establishment of intestinal microbiota during early life: a longitudinal, explorative study of a large cohort of Danish infants. Appl. Environ. Microbiol. 2014;80(9):2889-2900. https://doi.org/10.1128/AEM.00342-14
3. Faith J. J., Guruge J. L., Charbonneau M., Subramanian S., Seedorf H. [et al.]. The long-term stability of the human gut microbiota. Science. 2013;341(6141):1237439. https://doi.org/10.1126/science.1237439
4. Ding T., Schloss P. D. Dynamics and associations of microbial community types across the human body. Nature. 2014;509(7500):357-360. https://doi.org/10.1038/nature13178
5. Biagi E., Candela M., Fairweather-Tait S., Franceschi C., Brigidi P. Aging of the human metaorganism: the microbial counterpart. Age (Dordr). 2012;34(1):247-267. https://doi.org/10.1007/s11357-011-9217-5
6. Claesson M. J., Jeffery I. B., Conde S., Power S. E., O’Connor E. M. [et al.]. Gut microbiota composition correlates with diet and health in the elderly. Nature.2012;488(7410):178-184. https://doi.org/10.1038/nature11319
7. Vlasov A. A., Salikova S. P., Grinevich V. B., Bystrova O. V., Osipov G. A., Meshkova M. E. Gut microbiota and systemic inflammation in patients with chronic heart failure. Kardiologiia. – Cardiology. 2020;60(5):74-82. (In Russ.). https://doi.org/10.18087/cardio.2020.5.n859
8. Koeth R. A., Wang Z., Levison B. S., Buffa J. A., Org E. [et al.]. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med.2013;19(5):576-585. https://doi.org/10.1038/nm.3145
9. Wang Z., Zhao Y. Gut microbiota derived metabolites in cardiovascular health and disease. Protein. Cell. 2018;9(5):416-431. https://doi.org/10.1007/s13238-018-0549-0
10. Shilov A. M., Agasarov L. G., Petrukhina N. B., Zorina O. A. The place of dysbiosis of the digestive tract in the cardiovascular continuum. Vestnik novykh meditsinskikh tekhnologiy. – Bulletin of new medical technologies. 2014;1. Available at: https://cyberleninka.ru/article/n/mesto-disbioza-pischevaritelnogo-trakta-v-serdechno-sosudistom-kontinuume. (In Russ.).
11. Tang W. H., Kitai T., Hazen S. L. Gut Microbiota in Cardiovascular Health and Disease. Circ. Res.2017;120(7):1183-1196. https://doi.org/10.1161/CIRCRESAHA.117.309715
12. Lizogub V. G., Kramareva V. N., Melnichuk I. O. The role of intestinal microbiota changes in the pathogenesis of cardiovascular diseases (literature review). Zaporozhskiy meditsinskiy zhurnal. – Zaporozhye Medical Journal. 2019;21,5(116):672-678. (In Russ.). https://doi.org/10.14739/2310-1210.2019.5.179462
13. Mafra D., Lobo J. C., Barros A. F., Koppe L., Vaziri N. D., Fouque D. Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease. Future Microbiol. 2014;9(3):399-410. https://doi.org/10.2217/fmb.13.165
14. Qi J., You T., Li J., Pan T., Xiang L. [et al.]. Circulating trimethylamine N-oxide and the risk of cardiovascular diseases: a systematic review and meta-analysis of 11 prospective cohort studies. J. Cell. Mol. Med. 2018;22(1):185-194. https://doi.org/10.1111/jcmm.13307
15. Oynotkinova O. S, Nikonov E. L., Demidova T. Y., Baranov A. P., Kryukov E. V. [et al.]. Changes in the intestinal microbiota as a risk factor for dyslipidemia, atherosclerosis and the role of probiotics in their prevention. Terapevticheskii arkhiv. – Therapeutic archive.2020;92(9):94-101. (In Russ.). https://doi.org/10.26442/00403660.2020.09.000784
16. Kitai T., Tang W. H. W. Gut microbiota in cardiovascular disease and heart failure. Clin. Sci. (Lond). 2018;132(1):85-91. https://doi.org/10.1042/CS20171090
17. Tang W. H. W, Li D. Y., Hazen S. L. Dietary metabolism, the gut microbiome, and heart failure. Nat. Rev. Cardiol. 2019;16(3):137-154. https://doi.org/10.1038/s41569-018-0108-7
18. Oynotkinova O. Sh., Nikonov E. L., Gioeva I. Z. The role of gut microbiota in the pathogenesis of dyslipidemia and associated metabolic disorders. Dokazatel’naya gastroenterologiya. – Evidence-based gastroenterology.2017;2:29-34. (In Russ.). https://doi.org/10.17116/dokgastro20176229-34
19. Sun M., Wu W., Chen L., Yang W., Huang X. [et al.]. Microbiota-derived short-chain fatty acids promote Th1 cell IL-10 production to maintain intestinal homeostasis. Nat. Commun. 2018;9(1):3555. https://doi.org/10.1038/s41467-018-05901-2
20. Kaji I., Iwanaga T., Watanabe M., Guth P. H., Engel E. [et al.]. SCFA transport in rat duodenum. Am. J. Physiol. Gastrointest. Liver Physiol. 2015;308(3):188-197. https://doi.org/10.1152/ajpgi.00298.2014
21. Boyarintsev V. V., Yevseyev M. A. Metabolizm i nutritivnaya podderzhka khirurgicheskogo patsiyenta: Rukovodstvo dlya vrachey. SPb.: Onli-Press, 2017. (In Russ.).
22. Han H., Chen Y., Zhu J., Ni J., Sun J., Zhang R. Atorvastatin attenuates p‑cresyl sulfate‑induced atherogenesis and plaque instability in ApoE knockout mice. Mol. Med. Rep.2016;14(4):3122-3128. https://doi.org/10.3892/mmr.2016.5626
23. Han H., Zhu J., Zhu Z., Ni J., Du R. [et al.]. p-Cresyl sulfate aggravates cardiac dysfunction associated with chronic kidney disease by enhancing apoptosis of cardiomyocytes. J. Am. Heart. Assoc. 2015;4(6):e001852. https://doi.org/10.1161/JAHA.115.001852
24. Wang C. H., Cheng M. L., Liu M. H., Shiao M. S., Hsu K. H. [et al.]. Increased p-cresyl sulfate level is independently associated with poor outcomes in patients with heart failure. Heart. Vessels. 2016;31(7):1100-1108. https://doi.org/10.1007/s00380-015-0702-0
25. Kim H., Kim D. H., Seo K. H., Chon J. W., Nah S. Y. [et al.]. Modulation of the intestinal microbiota is associated with lower plasma cholesterol and weight gain in hamsters fed chardonnay grape seed flour. J. Agric. Food Chem.2015;63(5):1460-1467. https://doi.org/10.1021/jf5026373
26. Wang K., Yu X., Li Y., Guo Y., Ge L. [et al.]. Bifidobacterium bifidum TMC3115 Can Characteristically Influence Glucose and Lipid Profile and Intestinal Microbiota in the Middle-Aged and Elderly. Probiotics Antimicrob. Proteins.2019;11(4):1182-1194. https://doi.org/10.1007/s12602-018-9441-8
27. Su B., Liu H., Li J., Sunli Y., Liu B. [et al.]. Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus. J. Diabetes. 2015;7(5):729-739. https://doi.org/10.1111/1753-0407.12232
28. Robles-Vera I., Toral M., de la Visitación N., Sánchez M., Gómez-Guzmán M. [et al.]. Probiotics Prevent Dysbiosis and the Rise in Blood Pressure in Genetic Hypertension: Role of Short-Chain Fatty Acids. Mol. Nutr. Food Res.2020;64(6):e1900616. https://doi.org/10.1002/mnfr.201900616
29. Katsimichas T., Antonopoulos A. S., Katsimichas A., Ohtani T., Sakata Y., Tousoulis D. The intestinal microbiota and cardiovascular disease. Cardiovasc. Res. 2019;115(10):1471-1486. https://doi.org/10.1093/cvr/cvz135
30. Richards E. M., Pepine C. J., Raizada M. K., Kim S. The Gut, Its Microbiome, and Hypertension. Curr. Hypertens. Rep. 2017;19(4):36. https://doi.org/10.1007/s11906-017-0734-1
31. Lam V., Su J., Koprowski S., Hsu A., Tweddell J. S. [et al.]. Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J. 2012;26(4):1727-1735. https://doi.org/10.1096/fj.11-197921
32. Zhu Q., Gao R., Zhang Y., Pan D., Zhu Y. [et al.]. Dysbiosis signatures of gut microbiota in coronary artery disease. Physiol. Genomics. 2018;50(10):893-903. https://doi.org/10.1152/physiolgenomics.00070.2018
33. Liu H., Chen X., Hu X., Niu H., Tian R. [et al.]. Alterations in the gut microbiome and metabolism with coronary artery disease severity. Microbiome. 2019;7(1):68. https://doi.org/10.1186/s40168-019-0683-9
34. Li Y., Liu X., Du A., Zhu X., Yu B. miR-203 accelerates apoptosis and inflammation induced by LPS via targeting NFIL3 in cardiomyocytes. J. Cell. Biochem.2019;120(4):6605-6613. https://doi.org/10.1002/jcb.27955
35. Felisbino M. B., McKinsey T. A. Epigenetics in Cardiac Fibrosis: Emphasis on Inflammation and Fibroblast Activation. JACC Basic. Transl. Sci. 2018;3(5):704-715. https://doi.org/10.1016/j.jacbts.2018.05.003
36. Wang Y., Yin J., Wang C., Hu H., Li X. [et al.]. Microglial Mincle receptor in the PVN contributes to sympathetic hyperactivity in acute myocardial infarction rat. J. Cell. Mol. Med. 2019;23(1):112-125. https://doi.org/10.1111/jcmm.13890
37. Ye Y., Jia X., Bajaj M., Birnbaum Y. Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation. Cardiovasc. Drugs Ther. 2018;32(6):553-558. https://doi.org/10.1007/s10557-018-6837-3
38. Pastori D., Carnevale R., Nocella C., Novo M., Santulli M. [et al.]. Gut-Derived Serum Lipopolysaccharide is Associated With Enhanced Risk of Major Adverse Cardiovascular Events in Atrial Fibrillation: Effect of Adherence to Mediterranean Diet. J. Am. Heart Assoc. 2017;6(6):e005784. https://doi.org/10.1161/JAHA.117.005784
39. Yu L., Meng G., Huang B., Zhou X., Stavrakis S. [et al.]. A potential relationship between gut microbes and atrial fibrillation: Trimethylamine N-oxide, a gut microbe-derived metabolite, facilitates the progression of atrial fibrillation. Int. J. Cardiol. 2018;255:92-98. https://doi.org/10.1016/j.ijcard.2017.11.071
40. Zhu W., Wang Z., Tang W. H. W., Hazen S.L. Gut Microbe-Generated Trimethylamine N-Oxide From Dietary Choline Is Prothrombotic in Subjects. Circulation.2017;135(17):1671-1673. https://doi.org/10.1161/CIRCULATIONAHA.116.025338
41. Li X. S., Wang Z., Cajka T., Buffa J. A., Nemet I. [et al.]. Untargeted metabolomics identifies trimethyllysine, a TMAO-producing nutrient precursor, as a predictor of incident cardiovascular disease risk. JCI Insight. 2018;3(6):e99096. https://doi.org/10.1172/jci.insight.99096
42. Paramsothy S., Kamm M. A., Kaakoush N. O., Walsh A. J., van den Bogaerde J. [et al.]. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet.2017;389(10075):1218-1228. https://doi.org/10.1016/S0140-6736(17)30182-4
43. Zhu W., Gregory J. C., Org E., Buffa J. A., Gupta N. [et al.]. Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk. Cell. 2016;165(1):111-124. https://doi.org/10.1016/j.cell.2016.02.011
44. Sandek A., Swidsinski A., Schroedl W., Watson A., Valentova M. [et al.]. Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia. J. Am. Coll. Cardiol. 2014;64(11):1092-1102. https://doi.org/10.1016/j.jacc.2014.06.1179
45. Luedde M., Winkler T., Heinsen F. A., Rühlemann M. C., Spehlmann M. E. [et al.]. Heart failure is associated with depletion of core intestinal microbiota. ESC Heart Fail. 2017;4(3):282-290. https://doi.org/10.1002/ehf2.12155
46. Mayerhofer C. C. K., Kummen M., Holm K., Broch K., Awoyemi A. [et al.]. Low fibre intake is associated with gut microbiota alterations in chronic heart failure. ESC Heart Fail. 2020;7(2):456-466. https://doi.org/10.1002/ehf2.12596
47. Yang T., Santisteban M. M., Rodriguez V., Li E., Ahmari N. [et al.]. Gut dysbiosis is linked to hypertension. Hypertension. 2015;65(6):1331-1340. https://doi.org/10.1161/HYPERTENSIONAHA.115.05315
48. Kummen M., Mayerhofer C. C. K., Vestad B., Broch K., Awoyemi A. [et al.]. Gut Microbiota Signature in Heart Failure Defined From Profiling of 2 Independent Cohorts. J. Am. Coll. Cardiol. 2018;71(10):1184-1186. https://doi.org/10.1016/j.jacc.2017.12.057
49. Sandek A., Swidsinski A., Schroedl W., Watson A., Valentova M. [et al.]. Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia. J. Am. Coll. Cardiol. 2014;64(11):1092-1102. https://doi.org/10.1016/j.jacc.2014.06.1179
50. Tang W. H. W., Li D. Y., Hazen S. L. Dietary metabolism, the gut microbiome, and heart failure. Nat. Rev. Cardiol.2019;16(3):137-154. https://doi.org/10.1038/s41569-018-0108-7
51. Kamo T., Akazawa H., Suda W., Saga-Kamo A., Shimizu Y. [et al.]. Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure. PLoS One. 2017;12(3):e0174099. https://doi.org/10.1371/journal.pone.0174099
52. Mamic P., Heidenreich P. A., Hedlin H., Tennakoon L., Staudenmayer K. L. Hospitalized Patients with Heart Failure and Common Bacterial Infections: A Nationwide Analysis of Concomitant Clostridium Difficile Infection Rates and In-Hospital Mortality. J. Card. Fail. 2016;22(11):891-900. https://doi.org/10.1016/j.cardfail.2016.06.005
53. Engels C., Ruscheweyh H. J., Beerenwinkel N., Lacroix C., Schwab C. The Common Gut Microbe Eubacterium hallii also Contributes to Intestinal Propionate Formation. Front. Microbiol. 2016;7:713. https://doi.org/10.3389/fmicb.2016.00713
54. Egorova E. N., Mazur V. V., Kalinkin M. N., Mazur E. S. Role of endotoxin and systemic inflammation in chronic heart failure pathogenesis. Rossiyskiy kardiologicheskiy zhurnal. – Russian journal of cardiology. 2012;(3):25-27. (In Russ.).
55. Fadeeva M. V., Kudryavtseva A. V., Krasnov G. S., Skhirtladze M. R., Ivashkin V. T. Intestinal Microbiota in Patients with Chronic Heart Failure and Systolic Dysfunction. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. – Russian journal of gastroenterology, hepatology, coloproctology. 2020;30(2):35-44. (In Russ.). https://doi.org/10.22416/1382-4376-2020-30-2-35-44
56. Kitai T., Kirsop J., Tang W. H. Exploring the Microbiome in Heart Failure. Curr. Heart Fail. Rep. 2016;13(2):103-109. https://doi.org/10.1007/s11897-016-0285-9
57. Liu Z., Liu H. Y., Zhou H., Zhan Q., Lai W. [et al.]. ModerateIntensity Exercise Affects Gut Microbiome Composition and Influences Cardiac Function in Myocardial Infarction Mice. Front. Microbiol. 2017;8:1687. https://doi.org/10.3389/fmicb.2017.01687
58. Felizardo R. J. F., Watanabe I. K. M., Dardi P., Rossoni L. V., Câmara N. O. S. The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids. Pharmacol. Res. 2019;141:366-377. https://doi.org/10.1016/j.phrs.2019.01.019
59. Kain V., Van Der Pol W., Mariappan N., Ahmad A., Eipers P. [et al.]. Obesogenic diet in aging mice disrupts gut microbe composition and alters neutrophil:lymphocyte ratio, leading to inflamed milieu in acute heart failure. FASEB J. 2019;33(5):6456-6469. https://doi.org/10.1096/fj.201802477R

Keywords: gut microbiota, heart failure, gut microbiota metabolites, age aspects of the gut microbiome